Prot #AG-221-AML-004: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogen

  • Frankfurt, Olga (PD/PI)

Project: Research project

Project Details

Effective start/end date3/30/163/30/22


  • PPD Development (Prot #AG-221-AML-004 // Prot #AG-221-AML-004)
  • Celgene Corporation (Prot #AG-221-AML-004 // Prot #AG-221-AML-004)